Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Vaccines and Molecular Therapeutics

This article is part of the Research TopicTowards the Rapid and Systematic Assessment of Vaccine TechnologiesView all 15 articles

Yeast vaccine production platform for human and animal infectious diseases

Provisionally accepted
Abel Ramos VegaAbel Ramos Vega1,2*Elizabeth Monreal-EscalanteElizabeth Monreal-Escalante3Bernardo Bañuelos-HernándezBernardo Bañuelos-Hernández4Miriam AnguloMiriam Angulo3Edgar TrujilloEdgar Trujillo3Carlos AnguloCarlos Angulo3*
  • 1Instituto Politecnico Nacional, Mexico City, Mexico
  • 2Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada del IPN, Xochitepec, Morelos, Mexico
  • 3Centro de Investigaciones Biologicas del Noroeste SC, La Paz, Mexico
  • 4Universidad de La Salle, Bajío, Mexico

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Yeasts have contributed to human and animal health through functional antigen production for vaccine formulations. Some yeast-made vaccines have become a reality for humankind because they have reached commercialization (hepatitis B, HPV, and tick parasitosis). Many other vaccine prototypes are under preclinical and clinical evaluations, hoping for their usage soon. Currently, genomes, genetic modification techniques, and industrial vaccine manufacturing have been successfully developed for Saccharomyces cerevisiae, Komagataella phaffii (formerly Pichia pastoris), and Hansenula polymorpha. Moreover, several yeast species are under research as prospects for vaccine production systems, such as Kluyveromyces lactis, Yarrowia lipolytica, Schizosaccharomyces pombe, Saccharomyces boulardii, and Komagataella phaffii. This review was mainly focused on commercial human and animal vaccines, describing and discussing genetic engineering tools, downstream antigen purification processes, GMP according to regulatory issues, and identifying challenges and future directions on the use of yeast as a vaccine production platform to fight against infectious diseases.

Keywords: recombinant protein expression systems, biopharmaceuticals, eukaryotic cell factories, Immune responses, Human and animal health

Received: 01 Sep 2025; Accepted: 29 Oct 2025.

Copyright: © 2025 Ramos Vega, Monreal-Escalante, Bañuelos-Hernández, Angulo, Trujillo and Angulo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Abel Ramos Vega, aramosve@ipn.mx
Carlos Angulo, eangulo@cibnor.mx

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material